CoChat

Diabetes and obesity: therapeutic targeting and risk reduction – a complex interplay

Open access
Niswender, Kevin · 2010 · Diabetes, Obesity and Metabolism
Cited by 87

The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.

Abstract

Obesity is a major risk factor for the development of diabetes and predisposes individuals to hypertension and dyslipidaemia. Together these pathologies increase the risk for cardiovascular disease (CVD), the major cause of morbidity and mortality in type 2 diabetes mellitus (T2DM). Worsening trends in obesity and T2DM raise a serious conundrum, namely, how to control blood glucose, blood pressure, and lipids when many antidiabetic agents cause weight gain and thereby exacerbate other cardiovascular risk factors associated with T2DM. Further, evidence suggests that some established antihypertensive agents may worsen glucose intolerance. Many patients who are obese, hypertensive, and/or hyperlipidaemic fail to achieve blood pressure, lipid and glycaemic goals, and this failure may in part be explained by physician reluctance to utilize complex combination regimens for fear of off‐target effects. Thus, a clear need exists for clinicians to understand the risks and benefits of different pharmacologic, and indeed non‐pharmacologic, options in order to maximize treatment outcomes. While intensive lifestyle modification remains an elusive gold standard, newer diabetes targets, including the incretin axis, may offer greater cardiovascular risk reduction than other antidiabetes therapies, although definitive clinical trial data are needed. The glucagon‐like peptide‐1 (GLP‐1) receptor agonists exenatide and liraglutide and the dipeptidyl peptidase‐4 (DPP‐4) inhibitors sitagliptin and vildagliptin effectively lower HbA1c; exenatide and liraglutide reduce weight and blood pressure and improve lipid profiles. Sitagliptin and vildagliptin are weight neutral but also appear to improve lipid profiles. Integration of incretin therapies into the therapeutic armamentarium is a promising approach to improving outcomes in T2DM, and perhaps even in reducing complications of T2DM, such as co‐morbid hypertension and dyslipidaemia. Additional long‐term studies, including CVD end‐point studies, will be necessary to determine the appropriate places for incretin‐based therapies in treatment algorithms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2009.01175.x

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 82 references

Cited by

See all 87

Metadata

Authors
Niswender, K.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2010-02-25
Volume
12
Issue
4
Pages
267-287
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1993070711
Cited by
87
References
82
FWCI
5.44
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diabetes and obesity: therapeutic targeting and risk reduction – a complex interplay. https://app.cochat.ai/papers/10.1111/j.1463-1326.2009.01175.x
The paper
Niswender, K. (2010). Diabetes and obesity: therapeutic targeting and risk reduction – a complex interplay. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2009.01175.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.